Publications

Knotts T, Mease K, Sangameswaran L, Felx M, Kramer S, Donovan J. 2022. Pharmacokinetics and local tissue response to local instillation of vocacapsaicin, a novel capsaicin prodrug, in rat and rabbit osteotomy models. J Orthop Res 40(10):2281-2293; doi: 10.1002/jor.25271. PMID: 35128722.

Schaefer HR, Flannery BM, Crosby L, Jones-Dominic OE, Punzalan C, Middleton K. 2022. A systematic review of adverse health effects associated with oral cadmium exposure. Regul Toxicol Pharmacol 134(Oct):105243; doi: 10.1016/j.yrtph.2022.105243. PMID: 35981600.

Nicolas CI, Linakis MW, Minto MS, Mansouri K, Clewell RA, Yoon M, Wambaugh JF, Patlewicz G, et al. 2022. Estimating provisional margins of exposure for data poor chemicals using high throughput computational methods. Front Pharmacol 13(Oct 7):980747; doi: 10.3389/fphar.2022.980747. PMID: 36278238.

Moran KR, Wheeler MW. 2022. Fast increased fidelity samplers for approximate Bayesian Gaussian process regression. J Roy Stat Soc B 84(4):1198-228; doi: 10.1111/rssb.12494. PMCID: 36570797.

Danese MD, Schenfeld J, Shaw J, Gawade P, Balasubramanian A, Kelsh M, et al. 2022. Association between granulocyte colony-stimulating factor (G-CSF) use and myelodysplastic syndrome (MDS) or acute myeloid leukemia (AML) among elderly patients with breast, lung, or prostate cancer.  Adv Ther 39(6):2778–2795; doi:10.1007/s12325-022-02141-1. PMID: 35430673.

Schenfeld J, Gong T, Henry D, Kelsh M, Gawade P, Peng Y, Bradbury BD, Li S. 2022. Patterns of primary prophylactic granulocyte colony-stimulating factor use in older Medicare patients with cancer receiving myelosuppressive chemotherapy. Support Care Cancer 30(7):6327–6338; doi: 10.1007/s00520-022-06967-x. PMID: 35482126.

Pouillot R, Farakos SS, Spungen J, Schaefer HR, Flannery BM, Van Doren JM. 2022. Cadmium physiologically based pharmacokinetic (PBPK) models for forward and reverse dosimetry: Review, evaluation, and adaptation to the U.S. population. Toxicol Lett 367(Aug):67-75; doi: 10.1016/j.toxlet.2022.07.812. PMID: 35901988. Corrigendum: Toxicol Lett 2023 377(March):14-15; doi: 10.1016/j.toxlet.2023.01.011.

Reichert H, Suh M, Jiang X, Movva N, Bylsma LC, Fryzek JP, Nelson CB. 2022. Mortality associated with respiratory syncytial virus, bronchiolitis, and influenza among infants in the United States: A birth cohort study from 1998 to 2018. J Infect Dis 226(Suppl 2):S246–S254; doi: 10.1093/infdis/jiac127. PMID: 35968877.

Bylsma LC, Suh M, Movva N, Fryzek JP, Nelson CB. 2022. Mortality among United States infants and children under 5 years of age with respiratory syncytial virus and bronchiolitis: A systematic literature review. J Infect Dis 226(Suppl 2):S267–S281; doi: 10.1093/infdis/jiac226. PMID: 35968871.

Movva N, Suh M, Bylsma LC, Fryzek JP, Nelson CB. 2022. Systematic literature review of respiratory syncytial virus laboratory testing practices and incidence in United States infants and children <5 years of age. J Infect Dis 226(Suppl 2):S213–S224; doi: 10.1093/infdis/jiac203. PMID: 35968874.

Suh M, Movva N, Bylsma LC, Fryzek JP, Nelson CB. 2022. A systematic literature review of the burden of respiratory syncytial virus disease and health care utilization among United States infants younger than 1 year. J Infect Dis 226(Suppl 2):S195–S212; doi: 10.1093/infdis/jiac201. PMID: 35968876.

Suh M, Movva N, Jiang X, Reichert H, Bylsma LC, Fryzek JP, Nelson CB. 2022. Respiratory syncytial virus burden and healthcare utilization in United States infants, <1 year of age: Study of nationally representative databases, 2011–2019. J Infect Dis 226(Suppl 2):S184–S194; doi: 10.1093/infdis/jiac155. PMID: 35968879.

Movva N, Suh M, Reichert H, Hitze B, Sendak MP, Wolf Z, et al. 2022. Respiratory syncytial virus during the COVID-19 pandemic compared to historic levels: A retrospective cohort study of a health system. J Infect Dis 226(Suppl 2):S175–S183; doi: 10.1093/infdis/jiac220. PMID: 35968868.

Suh M, Movva N, Jiang X, Bylsma LC, Reichert H, Fryzek JP, Nelson CB. 2022. Respiratory syncytial virus (RSV) is the leading cause of United States infant hospitalizations 2009–2019: A study of the National (Nationwide) Inpatient Sample. J Infect Dis 226(Suppl 2):S154–S163; doi: 10.1093/infdis/jiac120. PMID: 35968878.

Wheeler MW, Cortiñas Abrahantes J, Aerts M, Gift JS, Allen Davis J. 2022. Continuous model averaging for benchmark dose analysis: Averaging over distributional forms. Environmetrics 33(5):e2728; doi: 10.1002/env.2728. PMCID: PMC9799099.

House JS, Grimm FA, Klaren WD, Dalzell A, Kuchi S, Zhang S, Lenz K, Boogaard PJ, Ketelsegers HB, Gant TW, Wright FA, Rusyn I. 2022. Grouping of UVCB substances with dose-response transcriptomics data from human cell-based assays. ALTEX 39(3):388-404; doi: 10.14573/altex.2107051. PMID: 35288757.

Rankin DA, Haddadin Z, Lipworth L, Stahl AL, Fryzek J, Suh M, et al. 2022. Comparison of clinical presentations and burden of respiratory syncytial virus in infants across three distinct healthcare settings in Davidson County, Tennessee. Therapeut Adv Infect Dis 9(July 18):20499361221112171; doi: 10.1177/20499361221112171. PMID: 35875809.

Ponder J, Rajagopal R, Singal M, Baker N, Patlewicz G, Roggen E, Cochrane S, Sullivan K. 2022. “In Litero” screening. Retrospective evaluation of clinical evidence to establish a reference list of human chemical respiratory sensitizers. Front Toxicol 4(Jul 15):916370; doi: 10.3389/ftox.2022.916370. PMID: 35910543.

Gupta N, Patel HD, Taylor J, Borin JF, Jacobsohn K,…, Price C, et al. 2022. Systematic review of the impact of a plant-based diet on prostate cancer incidence and outcomes. Prostate Cancer Prostatic Dis 25(3):444–452; doi: 10.1038/s41391-022-00553-2.

Karmaus A, Mansouri K, To K, Blake B, Fitzpatrick J, Strickland J, Patlewicz G, Allen D, et al. 2022. Evaluation of variability across rat acute oral systemic toxicity studies. Toxicol Sci 188(1):34-47; doi: 10.1093/toxsci/kfac042. PMID: 35426934.